New York, NY – November 5, 2025 — HITLAB, a global leader in digital health innovation and evidence generation, announced a strategic partnership with Immunogenik, Inc., a biotechnology company developing novel therapeutic platforms for aggressive cancers such as glioblastoma (GBM) and lung cancer brain metastasis.

The collaboration aims to advance Immunogenik’s technology, strengthen its clinical and regulatory readiness, and position the company for a Series A fundraising round of at least $10 million to support upcoming clinical trials, regulatory filings, and operational growth in the U.S. market.

“We are thrilled to partner with HITLAB to accelerate our mission of delivering next-generation cancer immunotherapies to patients facing some of the most devastating cancers,” said Dr. Jianping Huang, Founder and CEO of Immunogenik, Inc. “This collaboration provides the strategic, financial, and regulatory capacity as we move toward our upcoming clinical milestones and Series A financing .”

Immunogenik’s approach integrates biotechnology and clinical innovation to create first-in-class therapeutic platforms that target and destroy treatment-resistant cancer cells. The company’s research spans preclinical and clinical development, intellectual property creation, and collaborations with academic and research institutions to advance translational oncology discoveries.

Under the partnership, HITLAB will provide comprehensive advisory and evidence-generation support to position Immunogenik for sustainable growth and investor engagement. The scope of work includes:

• Financial Readiness & Capital Strategy:
• Regulatory and Data Room Preparation:
• Investor and Partner Engagement:

“Immunogenik’s science represents the kind of breakthrough innovation that has the potential to redefine cancer treatment,” said Stan Kachnowski, PhD, MPA, Chair of HITLAB. “Our partnership is focused on providing the strategic infrastructure and evidence generation needed to accelerate their path from discovery to patient impact.”